Chapter 44

Pharmacological Importance of Ketamine Loaded Nanoparticles

Asmara[1*], Laiba Fatima[2], Vishah Fatima[3], Maham Ahmed Butt[4], Anam Ghos[5], Muhammad Saleem[6], Muzammil Zaman Khan[7], Saad Hassan Qadir[8] and Muhammad Sikander Afzaal[9]

[1]Institute of Physiology and Pharmacology, University of Agriculture Faisalabad, Pakistan
[2]Department of Pharmacy, Faculty of Pharmacy, University of Lahore, Pakistan
[3]Department of Biochemistry, University of Agriculture Faisalabad, Pakistan
[4]Department of Pharmacy, Faculty of Pharmacy, University of Lahore, Pakistan
[5]Department of Parasitology, University of Agriculture Faisalabad, Pakistan
[6]Institute of Physiology and Pharmacology, University of Agriculture Faisalabad Pakistan
[7]Department of Pharmacy, University of Agriculture Faisalabad, Pakistan
[8]Department of Pharmaceutical Sciences, Faculty of Pharmacy, Superior University, Lahore, Pakistan
[9]Department of Pharmacy, Faculty of Pharmacy, University of Lahore, Pakistan
*Corresponding Author: asmarashahid005@gmail.com

ABSTRACT

Ketamine is an anesthetic that is utilized to enhance analgesia with a strong opioid-sparing effect in sub -anesthetic dosages and it's a latent treatment option. The brief in vivo elimination half-life of ketamine is an insufficiency. Therefore, our target was to improve ketamine-loaded polyethylene glycol (PEG)-(poly lactic-co-glycolic acid (PLGA) nanoparticles for sustained release that are both biocompatible and biodegradable. Our research exhibits that high drug loading and a sustained release profile are possible with ketamine-loaded PEG-PLGA nanoparticles produced using this novel nanoprecipitation method. Our conclusions show high ketamine encapsulation efficiency in the extended-release KSL preparation with continued release observed in mice consequently systematic management of doses that necessitates future investigation.

KEYWORDS
ketamine, analgesic, PEG-PLGA nanoparticles, Biocompatibility, Sustained release, High drug loading, Drug-loaded nanoparticles, Sustained release lipid particles

Received: 11-Jun-2024
Revised: 04-Jul-2024
Accepted: 11-Aug-2024

A Publication of Unique Scientific Publishers

Cite this Article as: Asmara, Fatima L, Fatima V, Butt MA, Ghos A, Saleem M, Khan MZ, Qadir SH and Afzaal MS, 2024. Pharmacological importance of ketamine loaded nanoparticles. In: Ahmed R, Khan A, Abbas RZ, Farooqi SH and Asrar R (eds), Complementary and Alternative Medicine: Nanotechnology-II. Unique Scientific Publishers, Faisalabad, Pakistan, pp: 383-390. https://doi.org/10.47278/book.CAM/2024.470

INTRODUCTION

A. Overview of Ketamine

Ketamine serves as a powerful antagonist of the N-Methyl-D-aspartate (NMDA) receptor that is given in complicated patients associated with moderate to severe cancer pain and utilized as an analgesic adjuvant through a neuropathic constituent. Preclinical studies have presented that comparatively ketamine easily allows it to pass across the Central nervous system barrier. In another study involving laboratory animals, antagonizing NMDA receptors of ketamine decreased resistance to the pain-relieving properties of narcotic medications, which resulted in reducing pain in combination with opioids. Still, in vivo, ketamine has a brief duration of time or lifespan where it is effectiveness increased as a prolonged analgesic therapy. Ketamine loaded-nanoparticles (NPs) were formed according to our new method. Briefly, ketamine hydrogen chlorid (HCl) was altered to the ketamine-free base form by regulating the pH to ~10 by adding 2 M NaOH dropwise (Riccardi et al., 2023).

B. Nanoparticle Drug Delivery Systems

During the last two years, drug delivery systems designed as Lipid-based have extensively developed with increasing achievement from liposomal and semi-solid lipid systems. Liposomes are made of phospholipids that spherical bilayer vesicles that are similar to human cell membrane structure. Another way is solid lipid systems may be sphere-shaped but then their composition can be unequal surfaces and various kinds of lipids with a neutral state, positive and negative charged, or zwitter ionic (Barkat et al., 2020). In contrast with the ketamine-loaded poly(lactic-co-glycolic acid)-based extended-release pharmaceutical delivery systems, the KSL system accomplished a loading of more than 70% drug concentration that system resolved the low loading downside in our earlier designed prolonged-release polymer-based ketamine preparations.

This system thoroughly recognized that the poor chemical stability of various liposomal drug delivery systems is a significant restriction, as disaggregation and substance or medication leakage are more giving rise because of bond hydrolysis. In settlement with others, we also have established a deprived relationship among laboratory and living organism behaviors of our lipid vesicle medicated drug delivery organism. In the physiological condition, a lipid membrane sink may be present which would temporarily limit the movement of the free drug and in vitro drug release process that is unlikely to be simulated effectively (Ezike et al., 2023).

Pharmacokinetics of Ketamine

A. Absorption, Distribution, Metabolism, and Excretion (ADME)

The pharmacokinetic parameters of ketamine or ketamine-loaded NPs. Ketamine administered intravenously was quickly reduced in ~30 min elimination of half-life and plasma absorptions of ketamine decreasing to under the lower limit of quantification as a result of 24 hrs post-dosing. The correlated systemic exposure (AUC 0-inf_obs) was 14.1 µg/mL h. These pharmacokinetic parameters for intravenous ketamine in mice are similar to those described by others (Han et al., 2020). By contrast, for ketamine-loaded PEG-PLGA nanoparticles or PEG-PLGA: SH nanoparticles, the elimination half-life was markedly longer at ~103 h and ~80 h respectively for released ketamine. Furthermore, in comparison to the same dose of i.v. ketamine itself, the systemic exposure (AUC0-inf_obs) values were approximately 10-fold higher at ~162 and ~137 µg/mL h. By extending the elimination half-life, boosting systemic exposure, and reducing clearance in contrast to the same dose of I.V. ketamine administered alone, the incorporation of ketamine into NPs improves its pharmacokinetic profile. When compared with the PEG-PLGA: SH nanoparticle, the elimination half-life and the systemic exposure of ketamine released from the PEGPLGA nanoparticles were longer (~20 h) and larger (~20%) respectively (Glue et al., 2021).



Fig. 1: lipid-based nanoparticles, (polyethylene glycol (PEG), arginine-glycine-aspartic acid (RGD))

B. Limitations of Conventional Ketamine Administration

With traditionally, these limitations improved the dissociative effects of acute Ketamine that give information about intranasal Ketamine 50mg in conjunction. For the treatment of treatment-resistant depression in combination through a conventional antidepressant, an enantiomer of racemic ketamine, was approved by the FDA. Furthermore, we developed hydromorphone-loaded PLGA-based sustained-release micro-particles. We also demonstrated that the concomitant of ketamine and the stout opioid analgesic by intrathecal, PLGA-based sustained-release microparticles show latent to enhance the liberation of else uncontrollable tumor-associated pain. Nonetheless, ketamine loading of these micro-particles was a shortage. On the way to account for such limitations, we offered that a superior outcome can produced by long-term relief of a liposomal-based delivery system and this revision was established to analyze our suggestion (Jelen and Stone, 2021).

Table 1: Types of Nanoparticles and their subtypes

Sr.	Hybrid NPs	Organic NPs	Inorganic NPs	References
1.	Hybrid NPs combine the characteristics of various NPs, including Lipid-polymer nanoparticles, Organic and inorganic nanoparticles, and Cell membrane-coated nanoparticles	This type of NPs contains Liposome-based NPs, Polymer-based nanoparticles including polymeric nanoparticles and polymeric micelles Dendrimers	These NPs contain Gold nanoparticles (Au NPs), Carbon nanotubes, Silica nanoparticles, Magnetic nanoparticles, and Quantum dots	(Yao et al., 2020) (Dristant et al., 2023b)

Nanoparticle Drug Delivery Systems

B. Advantages of Nanoparticle Delivery

In the treatment of disorders such as Cancer, optimal pharmacokinetics, accurate targeting of the tumor cells with reduced adverse reactions, and drug tolerance. NP-enhanced pharmaceutical delivery methods have clearly presented several advantages. The clinical management of various forms of cancer types includes various types i.e. organic and inorganic NPs. That has been thoroughly used as a priority during the process. As compared to conventional drugs with better PK parameters, tumor targeting, and bio-compatibility with stability. The Nano particles-based delivery systems have played a vital role in the significant reduction of systemic toxicity. They also have noticeable effects on drug resistance. These prominent characteristics of the NP-based drug delivery systems make them extensively capable of being applied for chemotherapy, Radiotherapy, gene therapy, hypothermia, and targeted therapy. Furthermore, drug resistance mechanisms including efflux transporters over NPs provide a better platform for combination therapy, which helps according to various methods or systems of multidrug tolerance (Raj et al., 2021). NPs contain a range of targeting and cytotoxic agents to overawed the issues correlated with drug resistance. In the recent few decades, NPs have been proven successful in diagnostics, procurement, and tumor targeting safely and effectively. They also have played a vital role in precise drug targeting with good Pharmacokinetics along with a significant decrease in adverse reactions as well as a reduction in drug tolerance. NP-based systems are designed and tailored based on the size and characteristics of tumors corresponding to their pathophysiology (Gavas et al., 2021).



Fig. 2: Ketamine encapsulated nanopolymers that were injected into rats to investigate their sustainability releases

Formulation and Characterization of Ketamine Loaded Nanoparticles

A. Selection of Nanoparticle Carrier

Multi-lamellar liposomes were opted for the requirement of specific large doses. Similar to some homogenous natural membranes, the stability of the liposomal structure helps in increasing the bilayer vigor by the use of cholesterol as well as restricted to poor-cholesterol spheres of bilayer organisms this one is unblended as well as interdigitated (Hallan et al., 2021). One description for such an anomaly is that bulky groups or certainly uniform more agglomerates are formed outside of the hydro-shell, diminish most of the bright signs, also condensed particles are not represented in the particle size distribution data [30–32]. TEM observed the characteristics of Nano-sized particles like shape and structure. We formed round particles that are prospective to be sphere-shaped in 3D astronomical. TEM recommends a size alteration that is more protruding compared with the mean Zeta score with standard deviation demonstrated and in arrangement using the high Power Distance Index. This existence of multi-lamellar liposomes is indicated by the variation of the proportion between 800 nm and 2 μm (Beaumont et al., 2021).

B. Ketamine Encapsulation Techniques

By a Shimadzu UV-2450 (Shimadzu Scientific Instruments, Columbia, MD) with concentration at λ max (268 nm), the ketamine concentrations were calculated by UV–visible spectroscopy (UV–Vis) and interpolated against a standard curve consisting of 8 concentrations (0–20 μg/mL) in triplicate.

The formula for calculating the Drug encapsulation efficiency (EE) was:

EE [weight (drug added) weight (drug un encapsulated)] = / [weight (drug added) based on PEG-PLGA, the small molecule, ketamine, can be successfully encapsulated at high drug loading (41.8%) into biodegradable NPs. Our results are aligned with previous findings by others demonstrating that PLGA in combination with PEG can improve drug release profiles. It is commonly known that by dissolving both drug and polymer in a suitable solvent, many small molecules can be encapsulated and then by using either emulsification methods or nanoprecipitation methods, drug-loaded polymeric nanoparticles are formed. Nonetheless, the drug loading is often very low (less than 5–10%) (Han et al., 2020). Our present work is novel in that by using our approach we have formed polymeric nanoparticles with high ketamine loading. Our data also demonstrate that ketamine-loaded PEG-PLGA and PEGPLGA: SH nanoparticles are appropriate for sustained release for approximately 21 days in vitro and 5 days in vivo. It has been reported the kinetics of medicine release, the particle size, shape, and type of polymers and their degradability all affect considerably. Furthermore, for better-sustained release, particle size and surface characteristics can be improved. Our PEG-PLGA and PEGPLGA: SH nanoparticles are around 100 nm in diameter. Because of their large surface area per unit volume, commonly small-size NPs would be predicted, they show a rapid release profile assisting an increased rate of water permeation and medium dissolution compared with larger particles. Nonetheless, the distribution of drugs and effects of drug release in the polymer matrix from NPs. As the encapsulated drug needs to diffuse through the polymer matrix, our method's unique drug-core polymer-shell structure produced a sustained release profile (Weng et al., 2020). Our hematological data were within the normal ranges for mice, which is consistent with the established safety profiles of the polymers utilized herein. Our method offers a simple way to increase the elimination half-life, the attainment of increased ketamine loading, and a sustained release profile is further confirmed and in this case of ketamine, the systemic exposure of drugs of interest markedly increases (Bernard et al., 2018).

C. Physicochemical Characterization Methods

NPs utilized in pharmaceutical delivery systems are typically intended or selected conventional on their size and physical properties to effectively target the pathology of tumors (Raj et al., 2021). Involuntarily, for the treatment of cancer (Dristant et al., 2023a), Nano-carriers are designed to target tumor cells over the transporter result of nanoparticles and the locating effect of the targeting material once immersed. Following, the drug is discharged to tumor cells to prompt killing. Medications placed with conventional antineoplastic drugs and genetic materials are contained within nanocarriers, this demonstrates their potential part in both cytotoxic and gene treatment (Amreddy et al., 2018). Meanwhile, for some drugs with low solubility, NPs provide a policy for certain drugs with low solubility, thereby facilitating their condensation and their distribution of drugs into blood circulation. Nanocarriers can enhance drug half-life and promote their growth within cancerous tissues also their purpose is to improve drug permeability and retention as a result of the size and surface features of NPs, Nano-carriers can proliferate the half-life of drugs and prompt their growth into tumor tissues (Shinde et al., 2021). In addition, the targeting system defends healthy cells against the cytotoxic effects of drugs; and reduces the negative side effects associated with cancer treatment. For instance, PEGylated liposomes containing doxorubicin effectively condensed cardiotoxicity associated with the free form of doxorubicin (D. Singh and Pahwa, 2020). In addition, nanoparticle albumin-bound paclitaxel demonstrated decreased adverse drug effects and permitted greater tolerated dosages compared to solvent-based Texans. Now accumulation to Chemotherapeutic and genetic therapies, different research has described the use of nanoparticle drugs in the field of immunotherapy and surgical procedure involving the removal of tissue for cancer (Gavas et al., 2021).

Pharmacological Importance of Ketamine Loaded Nanoparticles

A. Enhanced Bioavailability and Stability

Various liposomes in formulation sorts are offered, predominantly the capability to attain long-lasting release of the enclosed medication of concern short of conceding bioavailability invivo. This analysis shows that sustained-release

liposomes containing ketamine were formed effectively used for the initial expending the liable thin-film layer method. In mice, a 5-day post-administration duration was completed, in a continue-release profile the KSL preparation ensued in the systemic circulation along with a sort of muscles. As concerns the PK, the KSL preparation produced in a 27-folding proliferation in lethal half-life, a three-fold propagation in systemic exposure (AUC0−∞), and a three-fold reduction in clearance related through the consistent PK for an equal i.v dosage administered as per an aqueous solution of ketamine HCl. By using procedures planned somewhere else for the preparation of KSL in which the thin-film deposition procedure was utilized (Sharma et al., 2022). Low cholesterol-contented liposomes are preferred for improved consistency, a glycerol phospholipid (DSPC) and for the preparation of a raw lipid solution using cholesterol in a molar ratio containing 90%:10% was liquefied in 10 mL of ethanol by adequate shaky, the KSL system that one possibly will have reduced stability, therefore the lipids rapidly split and distributed, settled their drug content. Typically, one of the main limits is their poor chemical stability for many liposomal drug delivery systems, as a result of bond hydrolysis provides increased disintegration and drug percolation (Kaur et al., 2018).

B. Prolonged Therapeutic Effect

A wide variety of Nano carriers like lipid-based, polymeric, and inorganic the co-organization of these molecules and the distribution of drug therapies like chemotherapy and immunotherapy in similar organisms. To conclude, their is an affinity to the usage of biologically stimulated as well as resultant Nano carriers. In that analysis, we identify the different Nano systems in the field of immunotherapy that are recommended via sorts including polymeric and lipid-based Nano systems, metallic and inorganic Nano systems, and lastly, biologically stimulated and derivative nanovacc in the modern improvement (Y. Zhang et al., 2020). In recent decades, the utilization in nanotechnology have been improved the delivery of therapeutics, furthermore used in the treatment of diseases like cancer, by the improvement of various Nano carriers used for drug delivery applications (Raj et al., 2021). The purpose to develop an effective drug delivery system (DDS) is to concentrate on ensuring a larger insignificant circulation of the therapeutic agent to the target site or affected body part then eliminating minor distribution to non-targeted sites within the body. Various determinations have been dedicated to the development of Nano carriers that are capable of co-delivering chemotherapy drugs, cytokines, and antibodies. The usage of Nano carriers intended for drug delivery, particularly in the enlargement of dual therapeutic DDS is required after in two of these approaches for check-point inhibitors and other vaccines. The compensations derivative with the use of Nano carriers that are capability of the targeted delivery of therapeutic compounds such as the tumor microenvironment or the immune system cells, additionally, the immune stimulatory loading compounds in particulate carriers significantly develop their safety profile, consenting, in certain circumstances, an increase in the quantity of nanocarrier; to conclude, Nano carriers can serve as an adjuvant, decreasing the requirement for co-administration of adjuvants and antigens (Yetisgin et al., 2020).

C. Targeted Drug Delivery

Targeting of nanoparticle appliances can lead to enhancement in reversing multidrug resistance. Mechanisms of tumor drug resistance are more exposed, and NPs are greatly established for targeting these mechanics. Scientists are in progress for investigating the part of NPs in immunotherapy, which has a significant role in the treatment of cancer. NPs and hybrid-based nanoparticles have intended part for the delivery of drugs in chemotherapy, immunotherapy and targeted therapy have defined the nanoparticles-based targeting mechanisms of drug delivery and function in depressive drug resistance. In recent days, the cumulative number of tiny therapeutic drugs has gained entry in different clinical stages. Clinical trials of phase 1 are utilized for targeting the nanoparticles that are based on a system for delivery of small interfering RNA in the patients that have cancer shown in 2010. Testification of different clinical studies has great efficiency in the treatment of tumors by dynamically targeting the polymeric types nanoparticles comprising of chemotherapeutic docetaxel, associated with the solvent that based on DTXL Preparation (C. Zhang et al., 2022).

D. Reduced Side Effects and Toxicity

The nanoparticles that bind with albumin paclitaxel showed minor adverse effects, permitting the dose with a higher tolerance than that based on solvent Texans (Ghasemii et al., 2022). In addition to the chemotherapeutics and therapy of genes, different examinations had stated the implementation of the drugs with nanoparticles in immunotherapeutics and erosion of cancer treatment. When we combine immunotherapeutics and chemotherapeutics, this can treat cancer. Once examination shows that when co-directing the agents of chemotherapy based on the outline 3a and GM-CSF cytokine in the spearmint showed the modification of nanoparticles leading to the enhanced propagation of cytotoxic CDs(+) T cells and restoring the response of immune, directing the tumor necrosis and evading the cell of immune toxic. The combination of chemotherapeutics and immunotherapeutics includes the delivery of chemotherapy and monoclonal antibodies into the pores of nanoparticles of silicon (Chao et al., 2019).

D. Clinical Applications and Future Perspectives

Dependence is a significant barrier that delays the broader clinical use of KA as an antidepressant. Our research shows that nanotechnology-based drug delivery systems are essential for complex kinds of brain-related diseases. When predesigning the design of Nano carriers intended for drug delivery, we must primarily concentrate on two things: one simplifies the delivery of drugs to the specific brain sites related to the disease, while the other reduces the potential for

drugs to reach brain sites related to side effects. The current investigation, we applied a combination of mesoporous calcium-doped silica core, enzyme-responsive hyaluronic acid collaboration, receptor-mediated camouflage, and functional peptide tagging in the nanostructure. All of these approaches confirm that KA is efficiently inserted and transported within the brain. The best optimal of brain targeting spots is vital, with a focus on areas associated with diseases while slightly taking place in other unaffected regions. In our analysis, the N Methyl D Aspartate Receptor (NMDAR) was preferred as a targeting site due to its more occurrence in the hippocampus and prefrontal cortex compared to the VTA and NC, which is extremely associated with addiction or habit behavior. Peptide Con-G was preferred as the designated peptide for targeting as well as concentrating the multifunctional nanoparticles at the NMDAR site in the hippocampus and prefrontal cortex, whereas evading the VTA and NAc parts. Particularly, it is necessary to consider the synergistic outcome of all strategies on the nanostructure while raising Nanocarriers. If only a portion of the strategy is utilized, the recovery efficiency of depressed mice may be inadequate. After simple treatment with our nanoparticles, their activities and cognitive function displayed a significant improvement in the depressed mice that were almost nearly to a normal level. The effects of clinical studies have revealed that enhancement in cognitive function and antidepressant effects can last for approximately two weeks subsequently multiple series of repeated injections of KA over a 2–3 week period. In the future, our target is to regulate the duration for which these developed behaviors and cognitive functions can last following the implementation of the lateswhilet treatment using Nano carrier (Hanif et al., 2021).

Safety and Toxicity Considerations

A. Biocompatibility of Nanoparticles

Nanoparticles play a substantial role as a drug delivery system for the treatment of cancer. Nanoparticle-based drug delivery system has various benefits, similar to conventional drugs, including good solidity and enhanced biocompatibility, improved permeability and improved retention, and targeted delivery. The development and scope of hybrid nanoparticles, which include the collective characteristics of various NPs, have directed this particular drug delivery system to the above grade. Moreover, NPs utilized in pharmaceutical formulations serve a significant purpose in addressing drug resistance encountered in cancer chemotherapy. Polymer-based NPs are a different type of NP with specific structural arrangements for drug carriers designed by various monomers. Poly Lactic-co-glycolic acid (PLGA), a common polymeric nanoparticle, incorporates the co-polymerization of glycolic acid and lactic acid. PLGA is extensively used as a carrier for drug delivery due to its improved biocompatibility, stability, and biodegradation, as well as the EPR effect (Ibrahim and Abdellatif, 2021).

B. Potential Adverse Effects of Ketamine

In vivo, ketamine (KA) is broadly recognized for its short half-life. Frequently repetitive KA administration is essential to retain enhanced and long-lasting treatment outcomes. Still, the total amount of KA may repeatedly surpass the onset for harmless usage, causing potential impacts, including dissociative illusions, dependency, addiction, and cognitive diminishing. As a result of anxieties concerning its potential side effects, the FDA has authorized the use of KA exclusively in the treatment of treatment-resistant depression (TRD) or else main depressive disorder (MDD) in cases of severe thoughts of suicide or self-harm. Until now, the dosage of the antidepressant was insignificant. It is recognized that the effectiveness of antidepressant outcomes is mightily correlated to the dose and frequency at which patients follow them. A comprehensive and quantitative evaluate the efficiency of antidepressants and their impact on cognitive function retrieval depression in mice models. In this study, we tried to incorporate the results of individual behavior experiments into a merged index to estimate the efficacy of antidepressants and the recovery efficacy of cognitive function (Highland et al., 2019).

C. Long-term Safety and Efficacy Studies

Finding innovative and new cancer treatments is a main challenge throughout the globe. With the proliferation of various methodologies for cancer treatment and the conception of modified therapy approaches, the effectiveness of treatment for certain types of malignant tumors has significantly developed. SNPs are widely considered as a highly effective option for drug delivery as a result of their enhanced pharmacokinetic, and therapeutic efficiency, as such as high constancy. Furthermore, porous silicon nanoparticles have greatly exposed latent in the field of immunotherapy as a result of their immune adjuvant characteristics, containing the ability to promote antigen cross-presentation, facilitate lymphocyte polarization, and stimulate the secretion of interferon-γ (IFN-γ) (S. Singh et al., 2021). Both organic and inorganic nanoparticles have their unique benefits and drawbacks, the combination of the twofold in a hybrid-based drug delivery system provides a versatile carrier through enhanced biological characteristics; this can improve treatment efficiency and decrease drug resistance (Shi et al., 2020). Specially Targeting tumor cells is a vigorous property of nano-carriers used for pharmaceutical delivery systems, this one improves the efficiency of therapy whereas protects healthy cells from toxic side effects. While NC and non-natural antigen-presenting cells (APCs) have proved enhanced effectiveness than traditional immunotherapy, additional studies are needed to evaluate the clinical efficiency and patient tolerance of these innovative treatment methods. Furthermore, the development of NPs loaded with immunomodulatory factors might increase the efficacy of vaccines in immunotherapy. Consequently, there is a superior understanding of the tumor microenvironment (TME) and additional research on the relations between nanoparticle-based drug delivery systems and tumor immunity to improve drug strategy and manipulation (Lôbo et al., 2021).

Conclusion

Numerous kinds of nanoparticles, containing organic and inorganic nanoparticles, have previously been extensively utilized in clinical cancer-related types of treatment. Related to conventional drugs, the use of nanoparticles as a base of drug delivery systems is linked with enhanced PK, biocompatibility, cancer targeting, and consistency, even though instantaneously serves a major part in decreasing systemic toxicity and to overcome the challenge of antimicrobial tolerance. These benefits permit nanoparticle-based drug delivery to be broadly utilized in chemotherapy, targeted therapy, radiotherapy, hyperthermia, and gene therapy. Moreover, Nano carrier delivery systems arrange for upgraded stages used for combination treatment and also help overcome the resistance of drug mechanism, containing efflux carrier overexpression, malfunctioning apoptotic pathway, and hypoxia lump microenvironment. Based on several applications of multiple drug resistance (MDR), NPs loaded with various combinations of targeting agents and cytotoxic agents have been achieved to overcome the resistance of the drug. Through accumulative research, different types of hybrid nanoparticles have presented enhanced developments for delivery purpose and stimulated more consideration. Advanced research proceeding the biological properties of distinct cancers will result in more accurate drug research information. The main reasons influencing the interfaces between nanoparticles (NPs) and the immune system are the size, shape, composition, and surface characteristics of nanoparticles. While Nano vaccines as well as simulated APCs have established enhanced efficiency associated with traditional immunotherapy, further studies required in these new approaches for the treatment are insufficient in clinical efficiency, safety, and tolerance. Furthermore, increasing immunomodulatory factor-loaded NPs can increase the efficacy of vaccines intended for immunotherapy. Liposomes suggest various desired features in formulation, particularly concentrating on the capability to attain continuous release of the enclosed drug, deprived of conceding its effectiveness in the body. In this study, ketamine was effectively formed in liposomes expanding the standard thin-film coating system for the 1st time. The study demonstrated that the encapsulation and loading of medication in KSL achieved effectiveness rates of 65.6% and 72.4%, respectively . When inserted intravenously in mice, the KSL preparation ensued a prolonged-release profile in the systemic circulation, and various tissues of mice concluded for a period of 5 days after dosing. As regards the pharmacokinetics (PK), the KSL formulation produced a significant proliferation in terminal half-life, systemic exposure (AUC0−∞), and reduction in clearance related to the consistent PK of ketamine (KET) hydrochloric acid administered i.v. as a solution that has been dissolved in water for an equivalent dose. The tissue disposition information indicated that in elevation absorptions of KET were observed in the liver and brain as a result of 5 days following a single administration of the KSL preparation however not the ketamine HCl aqueous solution. Our prospective effort will concentrate on acquiring a better consideration of the production of this lipid particle to improve sensitivity into the detachment between the quick in vitro KET release and the elongated release from the KSL preparation in vivo.

REFERENCES

Amreddy, N., Babu, A., Muralidharan, R., Panneerselvam, J., Srivastava, A., Ahmed, R., Mehta, M., Munshi, A., and Ramesh, R. (2018). Recent advances in nanoparticle-based cancer drug and gene delivery. *Advances in Cancer Research*, *137*, 115–170.

Barkat, M. A., Das, S. S., Pottoo, F. H., Beg, S., and Rahman, Z. (2020). Lipid-based nanosystem as intelligent carriers for versatile drug delivery applications. *Current Pharmaceutical Design*, *26*(11), 1167–1180.

Beaumont, P., Courtois, A., Richard, T., Krisa, S., and Faure, C. (2021). Encapsulation of ε-viniferin into multi-lamellar liposomes: development of a rapid, easy and cost-efficient separation method to determine the encapsulation efficiency. *Pharmaceutics*, *13*(4), 566.

Bernard, M., Jubeli, E., Pungente, M. D., and Yagoubi, N. (2018). Biocompatibility of polymer-based biomaterials and medical devices–regulations, in vitro screening and risk-management. *Biomaterials Science*, *6*(8), 2025–2053.

Chao, J., Chow, W., Koczywas, M., Koehler, S., and Kim, H. (2019). Age-Related Changes in Nanoparticle Albumin Bound (nab) Paclitaxel Pharmacokinetics and Pharmacodynamics. *IRB*, *7157*(07/22), 19.

Dristant, U., Mukherjee, K., Saha, S., and Maity, D. (2023a). An overview of polymeric nanoparticles-based drug delivery system in cancer treatment. *Technology in Cancer Research and Treatment*, *22*, 15330338231152084.

Dristant, U., Mukherjee, K., Saha, S., and Maity, D. (2023b). An Overview of Polymeric Nanoparticles-Based Drug Delivery System in Cancer Treatment. *Technology in Cancer Research and Treatment*, *22*. https://doi.org/10.1177/15330338231152083

Ezike, T. C., Okpala, U. S., Onoja, U. L., Nwike, P. C., Ezeako, E. C., Okpara, J. O., Okoroafor, C. C., Eze, S. C., Kalu, O. L., and Odoh, E. C. (2023). Advances in drug delivery systems, challenges and future directions. *Heliyon*.

Gavas, S., Quazi, S., and Karpiński, T. M. (2021). Nanoparticles for cancer therapy: current progress and challenges. *Nanoscale Research Letters*, *16*(1), 173.

Ghasemii, K., Darroudi, M., Rahimmanesh, I., Ghomi, M., Hassanpour, M., Sharifi, E., Yousefiasl, S., Ahmadi, S., Zarrabi, A., and Borzacchiello, A. (2022). Advances in aptamer-based drug delivery vehicles for cancer therapy. *Biomaterials Advances*, *140*, 213077.

Glue, P., Russell, B., and Medlicott, N. J. (2021). Influence of formulation and route of administration on ketamine's safety and tolerability: systematic review. *European Journal of Clinical Pharmacology*, *77*, 671–676.

Hallan, S. S., Sguizzato, M., Esposito, E., and Cortesi, R. (2021). Challenges in the physical characterization of lipid nanoparticles. *Pharmaceutics*, *13*(4), 549.

Han, F. Y., Liu, Y., Kumar, V., Xu, W., Yang, G., Zhao, C.-X., Woodruff, T. M., Whittaker, A. K., and Smith, M. T. (2020). Sustained-release ketamine-loaded nanoparticles fabricated by sequential nanoprecipitation. *International Journal of Pharmaceutics*, *581*, 119291.

Hanif, S., Muhammad, P., Niu, Z., Ismail, M., Morsch, M., Zhang, X., Li, M., and Shi, B. (2021). Nanotechnology-based strategies for early diagnosis of central nervous system disorders. *Advanced NanoBiomed Research*, *1*(10), 2100008.

Highland, J. N., Morris, P. J., Zanos, P., Lovett, J., Ghosh, S., Wang, A. Q., Zarate Jr, C. A., Thomas, C. J., Moaddel, R., and Gould, T. D. (2019). Mouse, rat, and dog bioavailability and mouse oral antidepressant efficacy of (2R, 6R)-hydroxynorketamine. *Journal of Psychopharmacology*, *33*(1), 12–24.

Ibrahim, M. A., and Abdellatif, A. A. H. (2021). Applications of nanopharmaceuticals in delivery and targeting. *Nanopharmaceuticals: Principles and Applications Vol. 1*, 73–114.

Jelen, L. A., and Stone, J. M. (2021). Ketamine for depression. *International Review of Psychiatry*, *33*(3), 207–228. https://doi.org/10.1080/09540261.2020.1854194

Kaur, G., Grewal, J., Jyoti, K., Jain, U. K., Chandra, R., and Madan, J. (2018). Oral controlled and sustained drug delivery systems: Concepts, advances, preclinical, and clinical status. In *Drug Targeting and Stimuli Sensitive Drug Delivery Systems* (pp. 567–626). Elsevier.

Lôbo, G. C. N. B., Paiva, K. L. R., Silva, A. L. G., Simões, M. M., Radicchi, M. A., and Báo, S. N. (2021). Nanocarriers used in drug delivery to enhance immune system in cancer therapy. *Pharmaceutics*, *13*(8), 1167.

Raj, S., Khurana, S., Choudhari, R., Kesari, K. K., Kamal, M. A., Garg, N., Ruokolainen, J., Das, B. C., and Kumar, D. (2021). Specific targeting cancer cells with nanoparticles and drug delivery in cancer therapy. *Seminars in Cancer Biology*, *69*, 166–177.

Riccardi, A., Guarino, M., Serra, S., Spampinato, M. D., Vanni, S., Shiffer, D., Voza, A., Fabbri, A., and De Iaco, F. (2023). Narrative review: low-dose ketamine for Pain Management. *Journal of Clinical Medicine*, *12*(9), 3256.

Sharma, A., Verma, N., Chaturvedi, S., Prasad, N., and Rastogi, V. (2022). A Review on Polymeric Invasive and Non-Invasive Nanocarriers Assisted Transdermal Drug Delivery for Improved Penetration and Bioavailability. *Drug Delivery Letters*, *12*(1), 19–34.

Shi, Z., Zhou, Y., Fan, T., Lin, Y., Zhang, H., and Mei, L. (2020). Inorganic nano-carriers based smart drug delivery systems for tumor therapy. *Smart Materials in Medicine*, *1*, 32–47.

Shinde, A. S., Shinde, P. S., and Santra, T. S. (2021). Nanomaterials: versatile drug carriers for nanomedicine. *Nanomaterials and Their Biomedical Applications*, 253–296.

Singh, D., and Pahwa, S. (2020). A review on physico-chemical parameters of liposomal doxorubicin. *International Journal Applied Pharmacy*, *12*(2), 1–5.

Singh, S., Kumar, A., and Mittal, G. (2021). Ketamine-polymer based drug delivery system for prolonged analgesia: recent advances, challenges and future prospects. *Expert Opinion on Drug Delivery*, *18*(8), 1117–1130.

Wang, S., Duan, Y., Zhang, Q., Komarla, A., Gong, H., Gao, W., and Zhang, L. (2020). Drug Targeting via Platelet Membrane–Coated Nanoparticles. *Small Structures*, *1*(1), 1–15. https://doi.org/10.1002/sstr.202000018

Weng, J., Tong, H. H. Y., and Chow, S. F. (2020). In vitro release study of the polymeric drug nanoparticles: development and validation of a novel method. *Pharmaceutics*, *12*(8), 732.

Yao, Y., Zhou, Y., Liu, L., Xu, Y., Chen, Q., Wang, Y., Wu, S., Deng, Y., Zhang, J., and Shao, A. (2020). Nanoparticle-Based Drug Delivery in Cancer Therapy and Its Role in Overcoming Drug Resistance. In *Frontiers in Molecular Biosciences* (Vol. 7, p. 193). https://doi.org/10.3389/fmolb.2020.00193

Yetisgin, A. A., Cetinel, S., Zuvin, M., Kosar, A., and Kutlu, O. (2020). Therapeutic nanoparticles and their targeted delivery applications. *Molecules*, *25*(9), 2193.

Zhang, C., Xie, H., Zhang, Z., Wen, B., Cao, H., Bai, Y., Che, Q., Guo, J., and Su, Z. (2022). Applications and biocompatibility of mesoporous silica nanocarriers in the field of medicine. *Frontiers in Pharmacology*, *13*, 829796.

Zhang, Y., Liu, Y., and Liu, Y. (2020). Cyclodextrin-based multistimuli-responsive supramolecular assemblies and their biological functions. *Advanced Materials*, *32*(3), 1806158.